Syngenta Group's ambitious initial public offering (IPO) in Hong Kong, once projected to raise up to $10 billion, is reportedly facing further setbacks, potentially postponing the listing beyond the current year. This latest delay stems from lingering market volatility and difficulties in reaching a valuation that is agreeable to both the company and potential investors. The agricultural giant, owned by China's state-owned Sinochem, had initially aimed for a Shanghai listing, but withdrew that application in March 2024 due to China's economic slowdown and tighter IPO regulations on the mainland.
The current plan for a Hong Kong listing was intended to be one of the region's largest IPOs, with reports suggesting it could raise between $5 billion and $10 billion. The company had begun selecting banks for the potential offering as early as February 2026, with CICC and Goldman Sachs identified to lead the IPO, and Bank of America, CITIC Securities, and UBS also expected to play significant roles. Syngenta's move to Hong Kong was partly driven by a desire to reduce its Chinese ownership, which could help ease U.S. concerns amid heightened trade tensions.
Despite boosting its profit before the potential IPO, Syngenta's financial health, particularly its substantial net debt of $24.8 billion at the end of 2024, remains a factor. The company had planned to use part of the IPO proceeds to reduce this debt, as well as to fund research and development and potential acquisitions. Syngenta typically invests about $2 billion annually in R&D to expand its product pipeline. The continuous delays, however, introduce uncertainty regarding the timing and ultimate success of its public offering this year, reflecting the challenging global market conditions for large-scale IPOs.
